6th Annual Digestive Diseases: New Advances Conference

6th Annual Digestive Diseases: New Advances Conference is organized by Global Academy for Medical Education and will be held from Mar 15 - 16, 2019 at The Westin Philadelphia, Philadelphia, Pennsylvania, United States of America.

The target audience for this medical event is gastroenterologists, hepatologists, primary care physicians, internists, advanced practice nurses, nurses, pharmacists, and physician assistants involved in the diagnosis, evaluation, management, and treatment of patients with digestive diseases. This CME Conference has been approved for a maximum of 13.25 AMA PRA Category 1 Credits.

The complexity and magnitude of medical advances in the management of digestive diseases make it ever more challenging for clinicians to apply this tremendous amount of information to their practice. This activity will provide learners with a comprehensive overview of the state-of-the art advances in the diagnostic, therapeutic, and preventive modalities of digestive diseases based on the latest evidence, literature, and clinical research. A thorough review of the current treatment landscape is vital to both clinicians and patients who can benefit from the expansion of therapeutic options.

Topics include :
• Hepatitis B & C
• Heartburn
• Irritable Bowel Syndrome
• Alcoholic Liver Disease
• Cholangitis
• Colorectal Screening
• Cirrhosis
• Esophageal Disorders
• Pancreatitis
• Liver Transplant 
• Minimally Invasive Approaches
• Gut Microbiota and Liver Disease
• Cases and more!

Interactive sessions offer attendees the chance to ask difficult questions and discuss patient care options with the experts.

Learning Objectives :
Upon completion of this activity, participants should be better able to:
• Identify benefits and disadvantages of the various colon cleansing strategies.
• Outline the recommended screening tests for colorectal cancer.
• Identify and address barriers to colorectal cancer screening.
• Integrate current SCENIC international consensus recommendations for CRC screening in patients with IBD.
• Integrate evidence-based approach to the diagnosis of esophageal motility disorders.
• Discuss treatment strategies for patients with esophageal motility disorders.
• Delineate a noninvasive diagnostic approach for GERD.
• Differentiate between common gastrointestinal disorders: IBS, IBD, peptic ulcer disease.
• Describe new and emerging management strategies for IBS.
• Delineate the role of biosimilar therapies in the management of IBD.
• Review the most current perspectives and clinical guidelines for the management of inflammatory bowel disease (IBD).
• Integrate routine testing for H. pylori prior to and after treatment for peptic ulcer.
• Identify patients with peptic ulcer disease for whom PPIs are indicated.
• Describe expanded donor organ criteria and novel technologies for improved organ preservation.
• Discuss the emerging paradigm for diagnosis and management of acute pancreatitis.
• Identify appropriate candidates with acute pancreatitis for minimally invasive approaches to treatment.
• Integrate current approaches to the diagnosis and management of cirrhotic cardiomyopathy.
• Develop evidence-based prevention and management strategy for gut dysbiosis in liver disease
• Identify factors that may be used to predict which patients with compensated cirrhosis may transition to decompensated cirrhosis.
• Assess optimal management strategies for patients with decompensated cirrhosis and its consequences, including hepatic encephalopathy and hepatorenal syndrome.
• Outline the screening recommendations for hepatitis B.
• Discuss diagnostic and monitoring recommendations for HBV.
• Outline the treatment recommendations for HCV.
• Delineate factors that increase risk for HCC in order to optimize early recognition and diagnosis.
• Describe challenges in the management of hepatocellular carcinoma.
• Discuss populations at risk for NASH.
• Delineate treatment strategies for NASH.
• Develop a diagnostic evaluation strategy for patients suspected of having alcoholic hepatitis/advanced liver disease.
• Discuss medical treatments and lifestyle modifications to manage AH.
• Discuss pruritis as a potential symptom of primary biliary cholangitis (PBC).
• Identify first- and second-line treatments for PBC.

Speakers: Nikolaos Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP (Edin), David C. Metz, MD, James V. Guarrera, MD, FACS, Guadalupe Garcia-Tsao, MD, Vijay Shah, MD, Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF, David Kastenberg, MD, and more

Time: 6:15 am - 4:00 pm